[1] Brian E Ford, et al. Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge. Diabetes Obes Metab. 2020 Jun 10. DOI:
10.1111/dom.14111[2] Medicinal Chemistry, et al. Design and Development of the Glucokinase Activator AZD1656. Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 1, 185-220.
[3] Terri Mitchard, et al. The novel use of a heterozygous knockout mouse for embryofetal development assessment of a glucokinase activator. Birth Defects Res B Dev Reprod Toxicol. 2014 Apr;101(2):152-61. DOI:
10.1002/bdrb.21102[4] M. WARING. Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656[J]. MedChemComm, 2012, 3 1: 1077-1081. DOI:
10.1039/c2md20077e
